RenovoRx, Inc.
NCM: RNXTLive Quote
📈 ZcoreAI Score
Our AI model analyzes RenovoRx, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RNXT Z-Score →About RenovoRx, Inc.
Healthcare
Biotechnology
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
📊 Fundamental Analysis
RenovoRx, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 453.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -225.6%, which indicates that capital utilization is currently under pressure.
At a current price of $0.99, RNXT currently sits at the 38th percentile of its 52-week range (Range: $0.70 - $1.45).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$46.59M
Trailing P/E
--
Forward P/E
-8.21
Beta (5Y)
1.22
52W High
$1.45
52W Low
$0.70
Avg Volume
318K
Day High
Day Low